Abstract
Background
#Sucralfate is used as #adjunctivetherapy in the management of
#duodenalulcers [1]. Because sucralfate is an aluminum salt of sucrose
sulfate, the typical dosing regimen of 1 gram every 6 hours provides
approximately 828 mg of elemental aluminum (Al) daily; however less
than 0.02% is systemically absorbed [3]. This intake contributes to the
recommended daily intake of 0.12 mg aluminum/kg/day and #aluminumtoxicity has been previously reported as a known side effect of
sucralfate administration [2]. Aluminum toxicity is defined as an
aluminum
#bloodconcentration greater than 60 ng/mL. Neurologic abnormalities,
including #encephalopathy, confusion, and seizures, are the primary
presenting symptoms [3]. Aluminum toxicity with sucralfate has been
primarily described as a #chronictoxicity in patients with end stage
renal
disease (ESRD) due to multiple sources of aluminum combined with the
inability to properly excrete aluminum [1]. Historically, ESRD patients
faced high aluminum loads due to the use of aluminum containing
phosphate binders in addition to the high concentrations of aluminum in
the
dialysate fluids. Additionally, some non-aluminum containing medications
such as #ascorbicacid and #citricacid reduce Al3+ to Al2+, which leads
to enhanced gastrointestinal tract absorption [4].
For more Biomedical open access journals please click on
Acute Aluminum #Toxicity from Combination Therapy Sucralfate and Citric Acid in a #CardiacSurgery Patient by Andrea Sikora Newsome in BJSTR
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.